Free Trial
NASDAQ:NVCT

Nuvectis Pharma (NVCT) Stock Price, News & Analysis

Nuvectis Pharma logo
$7.78 +0.05 (+0.65%)
Closing price 04:00 PM Eastern
Extended Trading
$7.98 +0.20 (+2.57%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nuvectis Pharma Stock (NASDAQ:NVCT)

Key Stats

Today's Range
$7.48
$7.87
50-Day Range
$7.31
$10.95
52-Week Range
$4.44
$11.80
Volume
111,988 shs
Average Volume
265,095 shs
Market Capitalization
$162.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
Consensus Rating
Buy

Company Overview

Nuvectis Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

NVCT MarketRank™: 

Nuvectis Pharma scored higher than 51% of companies evaluated by MarketBeat, and ranked 512th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nuvectis Pharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Nuvectis Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Nuvectis Pharma are expected to grow in the coming year, from ($1.01) to ($0.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nuvectis Pharma is -6.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nuvectis Pharma is -6.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nuvectis Pharma has a P/B Ratio of 15.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Nuvectis Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    25.02% of the float of Nuvectis Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvectis Pharma has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nuvectis Pharma has recently increased by 24.53%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nuvectis Pharma does not currently pay a dividend.

  • Dividend Growth

    Nuvectis Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.02% of the float of Nuvectis Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvectis Pharma has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nuvectis Pharma has recently increased by 24.53%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nuvectis Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Nuvectis Pharma this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for NVCT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $615,781.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    30.52% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nuvectis Pharma's insider trading history.
Receive NVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter.

NVCT Stock News Headlines

Nuvectis Pharma Inc News (NVCT) - Investing.com
Altucher: Turn $900 into $108,000 in just 12 months?
Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.
See More Headlines

NVCT Stock Analysis - Frequently Asked Questions

Nuvectis Pharma's stock was trading at $5.41 on January 1st, 2025. Since then, NVCT stock has increased by 43.8% and is now trading at $7.78.

Nuvectis Pharma, Inc. (NASDAQ:NVCT) issued its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03.

Nuvectis Pharma (NVCT) raised $19 million in an IPO on Friday, February 4th 2022. The company issued 3,200,000 shares at $5.00-$7.00 per share.

Nuvectis Pharma's top institutional shareholders include Baldwin Wealth Partners LLC MA (1.68%). Insiders that own company stock include Marlio Charles Mosseri, Enrique Poradosu and Shay Shemesh.
View institutional ownership trends
.

Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvectis Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
5/06/2025
Today
7/25/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NVCT
CIK
1875558
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

High Price Target
$19.00
Low Price Target
$15.00
Potential Upside/Downside
+124.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-148.83%
Return on Assets
-95.60%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.28
Quick Ratio
3.28

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.50 per share
Price / Book
15.14

Miscellaneous

Outstanding Shares
20,890,000
Free Float
14,517,000
Market Cap
$158.14 million
Optionable
Not Optionable
Beta
-0.25
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:NVCT) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners